ON THE RELEVANCE OF 2ND-LINE CYTOTOXIC CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER RESISTANT TO STANDARD COMBINATIONS

  • 5 December 1986
    • journal article
    • research article
    • Vol. 98  (23) , 790-797
Abstract
85 clinical studies concerning second-line chemotherapy of metastatic breast cancer have been analyzed. With minor exceptions, the mean remission rates ranged between 0-10% (complete remission) and 20-40% (partial remission) for the most commonly used second-line chemotherapy modalities. The mean duration of response was 6 months, the average survival time 10 months. No significant differences in effectiveness and side effects were found when comparing the different second-line treatment programmes.